查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1830991

骨質疏鬆症治療市場

Osteoporosis Treatment Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

預計骨質疏鬆症治療市場將從 2024 年的 171.7 億美元成長到 2031 年的 227.2 億美元，2025 年至 2031 年的複合年成長率為 3.8%。

分析師觀點：本報告概述了當前骨質疏鬆症治療市場趨勢所驅動的成長機會及其在預測期內的預期影響。骨質疏鬆症會導致骨骼脆弱，即使是輕微的跌倒也可能導致骨折，嚴重影響生活品質。早期發現和治療可以減緩或阻止骨質疏鬆症的進展，從而降低骨折風險。因此，骨質疏鬆症盛行率的上升增加了對診斷的需求，這反過來又推動了骨質疏鬆症治療市場的成長。由於更年期荷爾蒙變化會影響骨密度，這種疾病主要見於女性。其他導致老年人骨質疏鬆症風險的因素包括類風濕性關節炎、家族病史、長期使用骨質疏鬆藥物。根據國際骨質疏鬆症基金會的數據，在骨質疏鬆症患者中，25% 為女性，5% 為 65 歲以上的男性。

市場概覽：骨質疏鬆症是一種進展性疾病，對男性、停經後女性和老年人而言，骨折風險較高。骨質疏鬆症患者尤其容易發生骨骼、髖部、前臂、脊椎和腕部骨折。它被歸類為一種代謝紊亂，會降低骨密度，從而導致骨折。治療方案通常包括雙磷酸鹽、荷爾蒙療法、地諾單抗和各種營養補充劑，以及生活方式的改變，例如增加體力活動和富含鈣的飲食。推動骨質疏鬆症治療市場成長的關鍵因素包括醫療保健在研究和藥物開發方面的支出不斷增加，以及人們對現有骨質疏鬆症治療方法的認知不斷提高。

策略洞察市場驅動力：骨質疏鬆症發病率上升和生活方式改變推動市場擴張。全球骨質疏鬆症的盛行率正在上升，主要原因是不健康的生活方式、營養不良、運動不足、鈣和維生素D攝取量低以及荷爾蒙失衡。國際骨質疏鬆症基金會報告稱，骨質疏鬆症每年導致超過890萬人骨折，相當於每三秒鐘就會發生一起骨質疏鬆性骨折，全球約有2億名女性受到影響。老年人口的增加是推動骨質疏鬆症治療市場成長的另一個重要因素。 Labiotech發表的一項名為《骨質疏鬆症研究進展》的研究表明，約有1000萬美國人患有骨質疏鬆症，其中約4400萬人骨密度低，這增加了他們患骨質疏鬆症的風險。骨質疏鬆症的可能性隨著年齡的成長而增加；50歲及以上的成年人骨折風險較高。在美國，65歲及以上髖部骨折患者中四分之三為女性，其中約15%至36%的患者會在一年內死亡。人們對整體健康和保健的日益關注推動了定期健康篩檢，包括骨密度評估。隨著人們越來越關注自身的骨骼健康，早期診斷和介入變得至關重要，這進一步推動了市場成長。人們對骨骼健康的認知不斷提高，對預防和治療解決方案的需求也隨之增加，這大大促進了骨質疏鬆症治療市場的發展。

節段分析：

透過檢查以下部分對骨質疏鬆症治療市場進行分析：藥物類別、類型、給藥途徑和配銷通路。

就藥物類別而言，骨質疏鬆症治療市場分為RANKL抑制劑、雙磷酸鹽類藥物、選擇性雌激素受體調節劑 (SERM)、荷爾蒙療法等。 RANKL類藥物在2023年佔據了最大的市場佔有率，而荷爾蒙療法類藥物預計在2023年至2031年期間的複合年成長率最高。雙磷酸鹽類藥物在骨質疏鬆症治療市場中也佔有相當大的佔有率。雙磷酸鹽類藥物，包括阿崙膦酸鹽和唑來膦酸，可有效抑制骨吸收、增強骨密度並降低骨折風險。其豐富的臨床應用、監管部門的批准以及口服和靜脈注射兩種劑型的可用性，使其成為醫療保健提供者的首選。此外，其成本效益和廣泛的保險覆蓋範圍也使其在骨質疏鬆症治療中廣泛使用。

市場依類型分為原發性骨質疏鬆症及繼發性骨質疏鬆症。 2023年，原發性骨質疏鬆症在骨質疏鬆症治療市場中佔有較大佔有率。原發性骨質疏鬆症與老化有關，導致骨骼更新逐漸下降。美國國家醫學圖書館發表的一項題為《停經後女性原發性骨質疏鬆症和低骨量患病率及相關風險因素》的研究表明，全球30%的50歲以上女性患有骨質疏鬆症，每年8%至9%的骨折歸因於此。此外，70歲及以上的男性和女性會經歷骨骼形成和流失之間的不平衡，導致背痛、生活品質下降和日常活動困難。

就給藥途徑而言，骨質疏鬆症治療市場分為口服和注射兩種形式。注射劑在2023年佔據了最大的市場佔有率，預計在2023年至2031年期間將實現最高的複合年成長率。注射劑的主導地位可歸因於其作為給藥方式的有效性和可靠性。透過注射給藥可使藥物直接進入血液，確保快速且可預測的吸收，這對骨質疏鬆症治療至關重要。此外，一些骨質疏鬆症藥物僅以注射劑形式提供，進一步提升了該領域的市場佔有率。隨著患者對自行注射的依從性的提高以及給藥技術的不斷進步，注射劑領域已做好準備，保持其強勁的市場佔有率。

區域分析：骨質疏鬆症治療市場報告涵蓋北美、歐洲、亞太地區、中東和非洲以及南美和中美。北美市場在 2023 年的價值為 82.6 億美元，預計到 2031 年將達到 112.6 億美元，2023 年至 2031 年期間的預期複合年成長率為 3.9%。推動該地區市場成長的一個重要因素是人口老化嚴重，加上人們對骨質疏鬆症的認知不斷提高。此外，先進的醫療基礎設施和全面的醫療服務有助於及時診斷和治療。大型製藥公司的存在和持續的研發努力也促進了創新療法的引入。此外，優惠的報銷政策和保險覆蓋為尋求骨質疏鬆症治療的患者提供支持，從而促進北美市場的成長。

亞太地區骨質疏鬆症治療市場預計將達到4.7%的最高複合年成長率。該地區，尤其是印度和中國等國家，擁有龐大的製藥產業，而中國是製造業中心。該地區的預期成長主要得益於蓬勃發展的中產階級和醫療服務可近性的改善。此外，醫療基礎設施的進步和新興製藥產業的蓬勃發展，使亞太地區成為骨質疏鬆症治療市場實現顯著成長和發展的關鍵地區。

骨質疏鬆症治療市場報告範圍關鍵參與者分析：骨質疏鬆症治療市場報告中介紹的關鍵參與者包括輝瑞公司、安進公司、卡迪拉製藥、禮來公司、第一三共株式會社、梯瓦製藥公司、旭化成株式會社、諾華公司、中外製藥公司有限公司。

最新動態：

骨質疏鬆症治療市場中的公司正將併購作為主要的成長策略。市場近期的發展包括：

2021年10月，知名生技公司Entera Bio宣布其中期口服骨質疏鬆症藥物製劑研究的重要資料，進入3期註冊階段。 2021年8月，印度藥品管理總局（DCGI）向Enzene Biosciences Ltd授予其生物相似藥Denosumab的上市許可（MA），用於治療成人骨質疏鬆症。 2021年1月，總部位於倫敦的製藥公司Theramex在歐洲推出了骨質疏鬆症藥物Livogiva。

目錄

第1章：簡介

第2章：執行摘要

  • 關鍵見解
  • 市場吸引力分析

第3章：研究方法

第4章：骨質疏鬆症治療市場格局

  • 概述
  • PEST分析
  • 生態系分析
    • 價值鏈中的供應商列表

第5章：骨質疏鬆症治療市場－關鍵市場動態

  • 關鍵市場促進因素
  • 主要市場限制因素
  • 關鍵市場機會
  • 未來趨勢
  • 促進因素和限制因素的影響分析

第6章：骨質疏鬆症治療市場－全球市場分析

  • 骨質疏鬆症治療 - 全球市場概覽
  • 骨質疏鬆症治療－全球市場及2031年預測

第7章：骨質疏鬆症治療市場-收入分析-依藥物類型，2021-2031

  • 概述
  • RANKL 抑制劑
  • 雙磷酸鹽
  • 荷爾蒙
  • 選擇性雌激素受體調節劑（SERM）
  • 其他

第 8 章：骨質疏鬆症治療市場 - 收入分析 - 依給藥途徑，2021-2031 年

  • 概述
  • 口服
  • 注射劑

第9章：骨質疏鬆症治療市場-收入分析-按類型，2021-2031

  • 概述
  • 原發性骨質疏鬆症
  • 繼發性骨質疏鬆症

第 10 章：骨質疏鬆症治療市場 - 收入分析 - 按配銷通路，2021-2031 年

  • 概述
  • 醫院
  • 零售藥局
  • 網路藥局

第 11 章：骨質疏鬆症治療市場 - 收入分析，2021-2031 - 地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 歐洲其他地區
  • 亞太
    • 澳洲
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第 12 章：產業格局

  • 併購
  • 協議、合作、合資企業
  • 新產品發布
  • 擴張和其他策略發展

第 13 章：競爭格局

  • 關鍵參與者的熱圖分析
  • 公司定位與集中度

第 14 章：骨質疏鬆症治療市場 - 主要公司簡介

  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Amgen Inc.
  • Cadila Pharmaceuticals
  • Daiichi Sankyo Company, Limited
  • Chugai Pharmaceuticals Co. Ltd.
  • Teijin Pharma Limited
  • Novartis AG
  • Eli Lily and Company
  • Asahi Kasei Pharma Corporation

第 15 章：附錄

簡介目錄
Product Code: TIPRE00004071

The osteoporosis treatment market is anticipated to grow from US$ 17.17 billion in 2024 to US$ 22.72 billion by 2031, reflecting a projected CAGR of 3.8% from 2025 to 2031.

Analyst Perspective:This report outlines growth opportunities driven by current trends in the osteoporosis treatment market and their expected effects during the forecast period. Osteoporosis can lead to fragile bones, making even minor falls potentially result in fractures, which can significantly impact quality of life. Early detection and treatment can slow or halt the progression of osteoporosis, thereby lowering fracture risk. Consequently, the rising prevalence of osteoporosis heightens the demand for diagnosis, which in turn propels the growth of the osteoporosis treatment market. This condition is predominantly seen in women due to hormonal changes during menopause that affect bone density. Other contributing factors to osteoporosis risk in older adults include rheumatoid arthritis, a family history of the disease, and prolonged use of medications that weaken bones. According to the International Osteoporosis Foundation, among those with osteoporosis, 25% are women and 5% are men aged over 65.

Market Overview:Osteoporosis is a progressive condition that poses a high risk of fractures in men, postmenopausal women, and the elderly. Patients with osteoporosis are particularly vulnerable to fractures in the bones, hips, forearms, spine, and wrists. It is classified as a metabolic disorder that reduces bone mineral density, leading to fractures. Treatment options typically include bisphosphonates, hormone therapy, denosumab, and various nutritional supplements, along with lifestyle changes such as increased physical activity and a diet rich in calcium. Key factors driving the growth of the osteoporosis treatment market include rising healthcare expenditures on research and drug development, as well as growing awareness of available osteoporosis treatments.

Strategic Insights Market Driver: Rising Incidence of Osteoporosis and Lifestyle Changes Fuel Market Expansion

The global prevalence of osteoporosis is on the rise, primarily due to unhealthy lifestyles, poor nutrition, insufficient exercise, low calcium and vitamin D intake, and hormonal imbalances. The International Osteoporosis Foundation reports that osteoporosis leads to over 8.9 million fractures annually, equating to one osteoporotic fracture every three seconds, affecting approximately 200 million women worldwide. The increasing elderly population is another significant factor contributing to the growth of the osteoporosis treatment market. A study published in Labiotech, "Advancements in Osteoporosis Research," indicates that around 10 million Americans have osteoporosis, with approximately 44 million having low bone density, heightening their risk for the disease. The likelihood of developing osteoporosis escalates with age; adults aged 50 and older are at a heightened risk for fractures. In the US, three-quarters of adults aged 65 and older who suffer hip fractures are women, with an estimated 15% to 36% of these patients dying within a year. A growing focus on holistic health and wellness promotes regular health screenings, including bone density assessments. As individuals increasingly monitor their bone health, early diagnosis and intervention become crucial, further driving market growth. The osteoporosis treatment market is significantly bolstered by heightened awareness of bone health, which fuels demand for both preventive and therapeutic solutions.

Segmental Analysis:

The analysis of the osteoporosis treatment market has been conducted by examining the following segments: drug class, type, route of administration, and distribution channel.

In terms of drug class, the osteoporosis treatment market is divided into RANKL inhibitors, bisphosphonates, selective estrogen receptor modulators (SERMs), hormone therapies, and others. The RANKL segment accounted for the largest market share in 2023, while the hormone therapies segment is projected to experience the highest CAGR from 2023 to 2031. The bisphosphonates segment also holds a significant share in the osteoporosis treatment market. Bisphosphonates, including alendronate and zoledronic acid, are effective in inhibiting bone resorption, enhancing bone density, and reducing fracture risk. Their extensive clinical history, regulatory approvals, and availability in both oral and intravenous forms make them a preferred choice among healthcare providers. Additionally, their cost-effectiveness and broad insurance coverage contribute to their widespread use in osteoporosis treatment.

The market is categorized by type into primary osteoporosis and secondary osteoporosis. The primary osteoporosis segment held a larger share of the osteoporosis treatment market in 2023. Primary osteoporosis is associated with aging, leading to a gradual decline in bone renewal. A study published in the National Library of Medicine titled "Prevalence of Primary Osteoporosis and Low Bone Mass in Postmenopausal Women and Associated Risk Factors" indicates that 30% of women over 50 globally have osteoporosis, with 8% to 9% of annual bone fractures attributed to this condition. Furthermore, men and women aged 70 and older experience an imbalance between bone formation and loss, resulting in back pain, diminished quality of life, and difficulties in daily activities.

Regarding the route of administration, the osteoporosis treatment market is divided into oral and injectable forms. The injectable segment held the largest market share in 2023 and is expected to register the highest CAGR from 2023 to 2031. The dominance of the injectable segment can be attributed to its effectiveness and reliability as a drug delivery method. Administering treatment via injections allows for direct entry of the drug into the bloodstream, ensuring rapid and predictable absorption, which is crucial in osteoporosis treatment. Additionally, some osteoporosis medications are exclusively available in injectable form, further enhancing this segment's market share. With improved patient compliance for self-administered injections and ongoing advancements in drug delivery technologies, the injectable segment is well-positioned to maintain its strong market presence.

Regional Analysis:The osteoporosis treatment market report encompasses North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The North American market was valued at US$ 8.26 billion in 2023 and is projected to reach US$ 11.26 billion by 2031, with an expected CAGR of 3.9% during 2023 to 2031. A significant factor driving market growth in this region is the large aging population, coupled with increased awareness of osteoporosis. Additionally, advanced healthcare infrastructure and comprehensive access to medical services facilitate timely diagnosis and treatment. The presence of major pharmaceutical companies and ongoing research and development efforts are also fostering the introduction of innovative therapies. Furthermore, favorable reimbursement policies and insurance coverage support patients seeking osteoporosis treatment, thereby promoting market growth in North America.

The Asia Pacific osteoporosis treatment market is anticipated to achieve the highest CAGR of 4.7%. This region, particularly countries like India and China, boasts a substantial pharmaceutical industry, with China serving as a manufacturing hub. The projected growth in this region is driven by a burgeoning middle class and improved access to healthcare. Moreover, advancements in healthcare infrastructure and the emerging pharmaceutical sector position the Asia Pacific as a key area for significant growth and development in the osteoporosis treatment market.

Osteoporosis Treatment Market Report Scope Key Player Analysis:Key players profiled in the osteoporosis treatment market report include Pfizer Inc., Amgen Inc., Cadila Pharmaceuticals, Eli Lilly and Company, Daiichi Sankyo Company, Limited, Teva Pharmaceuticals Inc., Asahi Kasei Corporation, Novartis AG, Chugai Pharmaceutical Co., Ltd., and Teijin Pharma Limited.

Recent Developments:

Companies in the osteoporosis treatment market are employing mergers and acquisitions as primary growth strategies. Recent developments in the market include:

In October 2021, Entera Bio, a prominent biotechnology firm, announced significant data from its mid-stage oral osteoporosis drug formulation study, advancing to Phase 3 registration.In August 2021, the Drug Controller General of India (DCGI) granted Marketing Authorization (MA) to Enzene Biosciences Ltd for its biosimilar drug Denosumab, indicated for osteoporosis treatment in adults.In January 2021, Theramex, a London-based pharmaceutical company, launched the osteoporosis drug Livogiva in Europe.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Osteoporosis Treatment Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Osteoporosis Treatment Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Osteoporosis Treatment Market - Global Market Analysis

  • 6.1 Osteoporosis Treatment - Global Market Overview
  • 6.2 Osteoporosis Treatment - Global Market and Forecast to 2031

7. Osteoporosis Treatment Market - Revenue Analysis (USD Million) - By Drug Type, 2021-2031

  • 7.1 Overview
  • 7.2 Rank Ligand (RANKL) Inhibitor
  • 7.3 Bisphosphonates
  • 7.4 Hormone
  • 7.5 Selective Estrogen Receptor Modulators (SERMs)
  • 7.6 Others

8. Osteoporosis Treatment Market - Revenue Analysis (USD Million) - By Route of Administration, 2021-2031

  • 8.1 Overview
  • 8.2 Oral
  • 8.3 Injectable

9. Osteoporosis Treatment Market - Revenue Analysis (USD Million) - By Type, 2021-2031

  • 9.1 Overview
  • 9.2 Primary Osteoporosis
  • 9.3 Secondary Osteoporosis

10. Osteoporosis Treatment Market - Revenue Analysis (USD Million) - By Distribution Channel, 2021-2031

  • 10.1 Overview
  • 10.2 Hospitals
  • 10.3 Retail Pharmacies
  • 10.4 Online Pharmacies

11. Osteoporosis Treatment Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

  • 11.1 North America
    • 11.1.1 North America Osteoporosis Treatment Market Overview
    • 11.1.2 North America Osteoporosis Treatment Market Revenue and Forecasts to 2031
    • 11.1.3 North America Osteoporosis Treatment Market Revenue and Forecasts and Analysis - By Drug Type
    • 11.1.4 North America Osteoporosis Treatment Market Revenue and Forecasts and Analysis - By Route of Administration
    • 11.1.5 North America Osteoporosis Treatment Market Revenue and Forecasts and Analysis - By Type
    • 11.1.6 North America Osteoporosis Treatment Market Revenue and Forecasts and Analysis - By Distribution Channel
    • 11.1.7 North America Osteoporosis Treatment Market Revenue and Forecasts and Analysis - By Countries
      • 11.1.7.1 United States Osteoporosis Treatment Market
        • 11.1.7.1.1 United States Osteoporosis Treatment Market, by Drug Type
        • 11.1.7.1.2 United States Osteoporosis Treatment Market, by Route of Administration
        • 11.1.7.1.3 United States Osteoporosis Treatment Market, by Type
        • 11.1.7.1.4 United States Osteoporosis Treatment Market, by Distribution Channel
      • 11.1.7.2 Canada Osteoporosis Treatment Market
        • 11.1.7.2.1 Canada Osteoporosis Treatment Market, by Drug Type
        • 11.1.7.2.2 Canada Osteoporosis Treatment Market, by Route of Administration
        • 11.1.7.2.3 Canada Osteoporosis Treatment Market, by Type
        • 11.1.7.2.4 Canada Osteoporosis Treatment Market, by Distribution Channel
      • 11.1.7.3 Mexico Osteoporosis Treatment Market
        • 11.1.7.3.1 Mexico Osteoporosis Treatment Market, by Drug Type
        • 11.1.7.3.2 Mexico Osteoporosis Treatment Market, by Route of Administration
        • 11.1.7.3.3 Mexico Osteoporosis Treatment Market, by Type
        • 11.1.7.3.4 Mexico Osteoporosis Treatment Market, by Distribution Channel
  • 11.2 Europe
    • 11.2.1 Germany
    • 11.2.2 France
    • 11.2.3 Italy
    • 11.2.4 Spain
    • 11.2.5 United Kingdom
    • 11.2.6 Rest of Europe
  • 11.3 Asia-Pacific
    • 11.3.1 Australia
    • 11.3.2 China
    • 11.3.3 India
    • 11.3.4 Japan
    • 11.3.5 South Korea
    • 11.3.6 Rest of Asia-Pacific
  • 11.4 Middle East and Africa
    • 11.4.1 South Africa
    • 11.4.2 Saudi Arabia
    • 11.4.3 U.A.E
    • 11.4.4 Rest of Middle East and Africa
  • 11.5 South and Central America
    • 11.5.1 Brazil
    • 11.5.2 Argentina
    • 11.5.3 Rest of South and Central America

12. Industry Landscape

  • 12.1 Mergers and Acquisitions
  • 12.2 Agreements, Collaborations, Joint Ventures
  • 12.3 New Product Launches
  • 12.4 Expansions and Other Strategic Developments

13. Competitive Landscape

  • 13.1 Heat Map Analysis by Key Players
  • 13.2 Company Positioning and Concentration

14. Osteoporosis Treatment Market - Key Company Profiles

  • 14.1 Teva Pharmaceutical Industries Ltd.
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 Pfizer Inc.
  • 14.3 Amgen Inc.
  • 14.4 Cadila Pharmaceuticals
  • 14.5 Daiichi Sankyo Company, Limited
  • 14.6 Chugai Pharmaceuticals Co. Ltd.
  • 14.7 Teijin Pharma Limited
  • 14.8 Novartis AG
  • 14.9 Eli Lily and Company
  • 14.10 Asahi Kasei Pharma Corporation

15. Appendix

  • 15.1 Glossary
  • 15.2 About The Insight Partners
  • 15.3 Market Intelligence Cloud